Graft vs Host Disease Treatment Market: By Drug Class (Monoclonal Antibodies, Immunosuppressive Drugs, Steroids, TNF Inhibitorso, Tyrosine Kinase Inhibitors Others) By Disease Type (Acute Graft vs Host Disease, Chronic Graft vs Host Disease) By Route of Administration (Oral, Parenteral) By Distribution Channel (Hospital Pharmacies, Retail Pharmacies Online Pharmacies) and Geography  

Purchase Option

$ 4400
$ 6600
$ 8900

Graft Vs Host Disease Treatment Market size was valued at USD x million in 2022 and is poised to grow at a CAGR of 7.08% from 2023-2029. Graft versus host disease is an immune-mediated disease. It is a medical complication in which there is a complex interaction between the donor and the adaptive immunity of the recipient. The disease occurs when the bone marrow or the stem cells are transplanted. The treatment using stem cells and bone marrow is used in the reconstruction of the damaged cells that surround the cancer cells. It is also used during solid organ transplantation. The chances of developing graft versus host disease are more in allogeneic transplantation.

Graft Vs Host Disease Treatment Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

8.1%

Largest Market

North America

Fastest Growing Market

Asia Pacific
Graft vs Host Disease Treatment Market Dynamics

Growing Number of Pipeline Drugs and Increasing Rate of Bone Marrow or Hematopoietic Stem Cell Treatment can drive the global Graft vs Host Disease Treatment market growth over the forecast years.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario

Graft Vs Host Disease Treatment Market Segmentation

By Drug Class
  • Monoclonal Antibodies,
  • Immunosuppressive Drugs,
  • Steroids,
  • TNF Inhibitors,
  • Tyrosine Kinase Inhibitors
  • Others
By Disease Type
  •  Acute Graft vs Host Disease,
  • Chronic Graft vs Host Disease.
By Route of Administration
  • Oral,
  • Parenteral
By Distribution Channel
  • Hospital Pharmacies,
  • Retail Pharmacies
  • Online Pharmacies

Frequently Asked Questions

The global Graft vs Host Disease Treatment market size is valued at USD 2,967.9 million in 2022

The major market players are Pfizer Inc., Novartis, Abbvie Inc., Sanofi (Kadmon Pharmaceuticals), Sanofi (Genzyme), Incyte Corporation, Bristol Myers Squibb Company, Genentech Inc., Astellas Pharma US Inc., and others.

The graft vs host disease treatment market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.

1. Executive Summary
2. Global Graft vs Host Disease Treatment Market Introduction
2.1. Global Graft vs Host Disease Treatment Market Taxonomy
2.2. Global Graft vs Host Disease Treatment Market Definitions
2.2.1. By Drug Class
2.2.2. By Disease Type
2.2.3. By Route of Administration
2.2.4. By Distribution Channel
2.2.5. By Region
3. Global Graft vs Host Disease Treatment Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Graft vs Host Disease Treatment Market Dynamic Factors - Impact Analysis
3.6. Global Graft vs Host Disease Treatment Market Competition Landscape
4. Global Graft vs Host Disease Treatment Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029
4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. Global Graft vs Host Disease Treatment Market, By Drug Class, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
5.1. Monoclonal Antibodies
5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Immunosuppressive Drugs
5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Steroids
5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. TNF Inhibitors
5.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. Tyrosine Kinase Inhibitors
5.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
5.6. Others
5.6.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.6.3. Market Opportunity Analysis
6. Global Graft vs Host Disease Treatment Market, By Disease Type, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
6.1. Acute Graft vs Host Disease
6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Chronic Graft vs Host Disease
6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
7. Global Graft vs Host Disease Treatment Market, By Route of Administration, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
7.1. Oral
7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Parenteral
7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
8. Global Graft vs Host Disease Treatment Market, By Distribution Channel, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
8.1. Hospital Pharmacies
8.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Retail Pharmacies
8.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Online Pharmacies
8.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
9. Global Graft vs Host Disease Treatment Market Forecast, By Region, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
9.1. North America
9.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.1.3. Market Opportunity Analysis
9.2. Europe
9.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.2.3. Market Opportunity Analysis
9.3. Asia-Pacific
9.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.3.3. Market Opportunity Analysis
9.4. Latin America
9.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.4.3. Market Opportunity Analysis
9.5. Middle East and Africa
9.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.5.3. Market Opportunity Analysis
9.6. Global Graft vs Host Disease Treatment Market - Opportunity Analysis Index, By Drug Class, Disease Type, Route of Administration, Distribution Channel, and Region, 2023 - 2029
10. North America Graft vs Host Disease Treatment Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
10.1. Drug Class Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Monoclonal Antibodies
10.1.2. Immunosuppressive Drugs
10.1.3. Steroids
10.1.4. TNF Inhibitors
10.1.5. Tyrosine Kinase Inhibitors
10.1.6. Others
10.2. Disease Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.2.1. Acute Graft vs Host Disease
10.2.2. Chronic Graft vs Host Disease
10.3. Route of Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.3.1. Oral
10.3.2. Parenteral
10.4. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.5.1. USA
10.5.2. Canada
10.6. North America Graft vs Host Disease Treatment Market - Opportunity Analysis Index, By Drug Class, Disease Type, Route of Administration, Distribution Channel, and Country, 2023 - 2029
10.7. North America Graft vs Host Disease Treatment Market Dynamics Trends
11. Europe Graft vs Host Disease Treatment Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
11.1. Drug Class Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Monoclonal Antibodies
11.1.2. Immunosuppressive Drugs
11.1.3. Steroids
11.1.4. TNF Inhibitors
11.1.5. Tyrosine Kinase Inhibitors
11.1.6. Others
11.2. Disease Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.2.1. Acute Graft vs Host Disease
11.2.2. Chronic Graft vs Host Disease
11.3. Route of Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.3.1. Oral
11.3.2. Parenteral
11.4. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
11.5.1. Germany
11.5.2. UK
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Russia
11.5.7. Rest of Europe
11.6. Europe Graft vs Host Disease Treatment Market - Opportunity Analysis Index, By Drug Class, Disease Type, Route of Administration, Distribution Channel, and Country, 2023 - 2029
11.7. Europe Graft vs Host Disease Treatment Market Dynamics Trends
12. Asia-Pacific Graft vs Host Disease Treatment Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
12.1. Drug Class Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Monoclonal Antibodies
12.1.2. Immunosuppressive Drugs
12.1.3. Steroids
12.1.4. TNF Inhibitors
12.1.5. Tyrosine Kinase Inhibitors
12.1.6. Others
12.2. Disease Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.2.1. Acute Graft vs Host Disease
12.2.2. Chronic Graft vs Host Disease
12.3. Route of Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.3.1. Oral
12.3.2. Parenteral
12.4. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
12.5.1. China
12.5.2. India
12.5.3. Japan
12.5.4. ASEAN
12.5.5. Australia & New Zealand
12.5.6. Rest of Asia-Pacific
12.6. Asia-Pacific Graft vs Host Disease Treatment Market - Opportunity Analysis Index, By Drug Class, Disease Type, Route of Administration, Distribution Channel, and Country, 2023 - 2029
12.7. Asia-Pacific Graft vs Host Disease Treatment Market Dynamics Trends
13. Latin America Graft vs Host Disease Treatment Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
13.1. Drug Class Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1. Monoclonal Antibodies
13.1.2. Immunosuppressive Drugs
13.1.3. Steroids
13.1.4. TNF Inhibitors
13.1.5. Tyrosine Kinase Inhibitors
13.1.6. Others
13.2. Disease Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.2.1. Acute Graft vs Host Disease
13.2.2. Chronic Graft vs Host Disease
13.3. Route of Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.3.1. Oral
13.3.2. Parenteral
13.4. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Latin America Graft vs Host Disease Treatment Market - Opportunity Analysis Index, By Drug Class, Disease Type, Route of Administration, Distribution Channel, and Country, 2023 - 2029
13.7. Latin America Graft vs Host Disease Treatment Market Dynamics Trends
14. Middle East and Africa Graft vs Host Disease Treatment Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
14.1. Drug Class Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
14.1.1. Monoclonal Antibodies
14.1.2. Immunosuppressive Drugs
14.1.3. Steroids
14.1.4. TNF Inhibitors
14.1.5. Tyrosine Kinase Inhibitors
14.1.6. Others
14.2. Disease Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
14.2.1. Acute Graft vs Host Disease
14.2.2. Chronic Graft vs Host Disease
14.3. Route of Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.3.1. Oral
14.3.2. Parenteral
14.4. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.4.1. Hospital Pharmacies
14.4.2. Retail Pharmacies
14.4.3. Online Pharmacies
14.5. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
14.5.1. Gulf Cooperation Council (GCC) Countries
14.5.2. South Africa
14.5.3. Rest of MEA
14.6. MEA Graft vs Host Disease Treatment Market - Opportunity Analysis Index, By Drug Class, Disease Type, Route of Administration, Distribution Channel, and Country, 2023 - 2029
14.7. MEA Graft vs Host Disease Treatment Market Dynamics Trends
15. Competition Landscape
15.1. Strategic Dashboard of Top Market Players
15.2. Company Profiles (Introduction, Financial Analysis, Key Offerings, Key Developments, Strategies, and SWOT Analysis)
15.2.1. F. Hoffmann-La Roche Ltd.
15.2.2. AbbVie, Inc.
15.2.3. Bristol-Myers Squibb
15.2.4. Pfizer, Inc.
15.2.5. Baxter International plc
15.2.6. Novartis AG
15.2.7. Eli Lilly and Co.
15.2.8. Shire plc
15.2.9. Alleran plc
15.2.10. Caladrius
15.2.11. Eisai
15.2.12. Anterogen
16. Research Methodology
17. Key Assumptions and Acronyms
  • Hoffmann-La Roche Ltd.
  • AbbVie, Inc.
  • Bristol-Myers Squibb
  • Pfizer, Inc.
  • Baxter International plc
  • Novartis AG
  • Eli Lilly and Co.
  • Shire plc
  • Alleran plc
  • Caladrius
  • Eisai
  • Anterogen

Adjacent Markets